Stock Screener ETF Screener

Penny Stock Screener Technical Analysis Screener

Dividend Center Best Dividend Stocks

Best High Yield Dividend Stocks Dividend Aristocrats Dividend Stock Comparison

Dividend Calculator Dividend Returns Comparison Dividend Calendar

My Experts Top Analysts Top Financial Bloggers Top-Performing Corporate Insiders Top Hedge Fund Managers Top Research Firms Top Individual Investors

Trending News

Education

Personal Finance How To Use TipRanks TipRanks Labs Webinar Center Glossary FAQs

About Us

About TipRanks Contact Us Careers Reviews Mobile APP

Working with TipRanks

Enterprise Solutions Advertise with Us Top Online Brokers Become an Affiliate TipRanks News Wire

Follow Us

TOOLS

Top Insiders Stocks

Notification Center

Penny Stock Screener

Technical Analysis Screener

Top Analyst Stocks

Top Smart Score Stocks

Top Insiders Stocks

Trending Stocks

Daily Analyst Ratings

Daily Insiders Trades

Dividend Stocks

Top Gainers/losers/active ETFs

Dividend Calculator

Options Profit Calculator

Dollar Cost Averaging

Compound Interest Calculator

Mortgage Calculator

Auto Loan Calculator

Student Loan Calculator

401k Retirement Calculator

Earnings Calendar

Dividend Calendar

Economic Calendar

Market Holidays

Dividend Center

Best Dividend Stocks

Best High Yield Dividend Stocks

Dividend Aristocrats

Dividend Stock Comparison

Dividend Calculator

Dividend Returns Comparison

Dividend Calendar

Top Financial Bloggers

Top-Performing Corporate Insiders

Top Hedge Fund Managers

Top Research Firms

Top Individual Investors

Personal Finance Center

Investing & Retirement

Spending & Savings

Top Online Brokers

Enterprise Solutions

Plans & Pricing

Education

How To Use TipRanks

About Us

Working with TipRanks

Enterprise Solutions

Top Online Brokers

Become an Affiliate

TipRanks News Wire

Follow Us

STOCKS

Oxford BioMedica plc (GB:OXB)

LSE:OXB

UK Market

OXB

Oxford BioMedica

Analyst Forecasts

Technical Analysis

Historical Prices

RESEARCH TOOLS

Top Analyst Stocks

Top Smart Score Stocks

reports

GB:OXB Dividends

Oxford BioMedica (OXB) Share Forecast & Price Target

58 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

OXB Analyst Ratings

Moderate Buy

2 Buy

0 Hold

0 Sell

Based on 2 analysts giving stock ratings to

Oxford

BioMedica

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

OXB Stock 12 Month Forecast

Average Price Target

650.23p

▲(118.56% Upside)

Based on 2 Wall Street analysts offering 12 month price targets for Oxford BioMedica in the last 3 months. The average price target is 650.23p with a high forecast of 800.00p and a low forecast of 500.00p. The average price target represents a 118.56% change from the last price of 297.50p.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"167":"167p","800":"800p","325.25":"325.3p","483.5":"483.5p","641.75":"641.8p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":799.999994760128,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">800.00p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":650.22708998,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">650.23p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":499.99999672508,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">500.00p</span>\n  </div></div>","useHTML":true}}],"tickPositions":[167,325.25,483.5,641.75,800],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2023","6":"May<br/>2024","9":"Oct<br/>2024","12":"Apr<br/>2025","25":"Apr<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,291,330.15384575077906,369.3076915015581,408.4615372523372,447.6153830031163,486.76922875389533,525.9230745046744,565.0769202554535,604.2307660062326,643.3846117570116,682.5384575077907,721.6923032585698,760.8461490093489,{"y":799.999994760128,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,291,318.6328530753846,346.26570615076923,373.89855922615385,401.53141230153847,429.164265376923,456.7971184523077,484.42997152769226,512.0628246030769,539.6956776784615,567.328530753846,594.9613838292307,622.5942369046154,{"y":650.22708998,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,291,307.07692282500614,323.15384565001233,339.23076847501846,355.3076913000246,371.3846141250308,387.46153695003693,403.53845977504307,419.6153826000492,435.6923054250554,451.76922825006153,467.8461510750677,483.92307390007386,{"y":499.99999672508,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":195.8,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":195.8,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":195.8,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":168,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":171,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":196,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":287,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":372,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":327,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":381.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":405,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":425.5,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":291,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target800.00p

Average Price Target650.23p

Lowest Price Target500.00p

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Detailed List of Analyst Forecasts

xxxxxxxxxxxxxxxxxx

RBC Capital

Reiterated

04/14/25

xxxxxxxxxxxxxxxxxx

Stifel Nicolaus

Stifel Nicolaus

Reiterated

04/09/25

J.P. Morgan Analyst forecast on GB:OXB

J.P. Morgan

450p→490p

Hold

64.71%

Upside

Reiterated

12/03/24

Oxford Biomedica (OXB:LN) (OXBDF) PT Raised to GBP4.90 at JPMorganJPMorgan analyst James Gordon raised the price target on Oxford Biomedica (OXB:LN) (OTC: OXBDF) to GBP4.90 (from GBP4.50) while maintaining a Neutral rating.

Deutsche Bank

250p→380p

Hold

27.73%

Upside

Reiterated

09/24/24

Oxford Biomedica price target raised to 380 GBp from 250 GBp at Deutsche BankOxford Biomedica price target raised to 380 GBp from 250 GBp at Deutsche Bank

Investec

366p

Buy

23.03%

Upside

Upgraded

05/08/24

Oxford Biomedica upgraded to Buy from Hold at InvestecOxford Biomedica upgraded to Buy from Hold at Investec

Ranks

Any

Any

Analyst Rating

Any

Any

Upside/ Downside

Any

Any

Action

Any

Any

xxxxxxxxxxxxxxxxxx

RBC Capital

Reiterated

04/14/25

xxxxxxxxxxxxxxxxxx

Stifel Nicolaus

Stifel Nicolaus

Reiterated

04/09/25

J.P. Morgan Analyst forecast on GB:OXB

J.P. Morgan

450p→490p

Hold

64.71%

Upside

Reiterated

12/03/24

Oxford Biomedica (OXB:LN) (OXBDF) PT Raised to GBP4.90 at JPMorganJPMorgan analyst James Gordon raised the price target on Oxford Biomedica (OXB:LN) (OTC: OXBDF) to GBP4.90 (from GBP4.50) while maintaining a Neutral rating.

Deutsche Bank

250p→380p

Hold

27.73%

Upside

Reiterated

09/24/24

Oxford Biomedica price target raised to 380 GBp from 250 GBp at Deutsche BankOxford Biomedica price target raised to 380 GBp from 250 GBp at Deutsche Bank

Investec

366p

Buy

23.03%

Upside

Upgraded

05/08/24

Oxford Biomedica upgraded to Buy from Hold at InvestecOxford Biomedica upgraded to Buy from Hold at Investec

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Oxford BioMedica

Which Analyst Should I Follow If I Want to Buy GB:OXB and Sell After:

1 Month

Success Rate

9/21 ratings generated profit

Average Return

+1.16%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 42.86% of your transactions generating a profit, with an average return of +1.16% per trade.

3 Months

Success Rate

12/21 ratings generated profit

Average Return

+1.26%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +1.26% per trade.

1 Year

Charles WestonRBC Capital

Success Rate

7/21 ratings generated profit

Average Return

-4.03%

reiterated a buy rating 17 days ago

Copying Charles Weston's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -4.03% per trade.

2 Years

Success Rate

4/21 ratings generated profit

Average Return

-29.25%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 19.05% of your transactions generating a profit, with an average return of -29.25% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

OXB Analyst Recommendation Trends

Rating

Sep 24

Oct 24

Nov 24

Dec 24

Apr 25

Strong Buy

5

3

3

1

3

Buy

0

0

1

1

1

Hold

3

2

2

2

1

Sell

0

0

0

0

0

Strong Sell

0

0

0

0

0

total

8

5

6

4

5

In the current month, OXB has received 4 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. OXB average Analyst price target in the past 3 months is 650.23.

Each month's total comprises the sum of three months' worth of ratings.

OXB Financial Forecast

OXB Earnings Forecast

Next quarter’s earnings estimate for OXB is -0.08p with a range of -0.08p to -0.08p. The previous quarter’s EPS was -0.31p. OXB beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.52% of the time in the same period. In the last calendar year OXB has Preformed in-line its overall industry.

Next quarter’s earnings estimate for OXB is -0.08p with a range of -0.08p to -0.08p. The previous quarter’s EPS was -0.31p. OXB beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.52% of the time in the same period. In the last calendar year OXB has Preformed in-line its overall industry.

OXB Sales Forecast

Next quarter’s sales forecast for OXB is 77.20M with a range of 77.20M to 77.20M. The previous quarter’s sales results were 50.81M. OXB beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.94% of the time in the same period. In the last calendar year OXB has Outperformed its overall industry.

Next quarter’s sales forecast for OXB is 77.20M with a range of 77.20M to 77.20M. The previous quarter’s sales results were 50.81M. OXB beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.94% of the time in the same period. In the last calendar year OXB has Outperformed its overall industry.

OXB Stock Forecast FAQ

What is GB:OXB’s average 12-month price target, according to analysts?

Based on analyst ratings, Oxford BioMedica plc’s 12-month average price target is 650.23.

What is GB:OXB’s upside potential, based on the analysts’ average price target?

Oxford BioMedica plc has 118.56% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Oxford BioMedica plc a Buy, Sell or Hold?

Oxford BioMedica plc has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.

What is Oxford BioMedica plc’s share price target?

The average share price target for Oxford BioMedica plc is 650.23. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is 800.00p ,and the lowest forecast is 500.00p. The average share price target represents 118.56% Increase from the current price of 297.5p.

What do analysts say about Oxford BioMedica plc?

Oxford BioMedica plc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.

How can I buy shares of Oxford BioMedica plc?

To buy shares of GB:OXB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing